Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 217-588-1 | CAS number: 1897-45-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 5 Mar 1982 to 3 Sep 1982
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 983
- Report date:
- 1983
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Groups of Sprague-Dawley rats (25 per sex per dose) were exposed by admixture with the diet for 13 weeks of treatment followed by a 13-week withdrawal period for rats not killed at week 6 or 13 (no guideline, non-GLP). Exposure levels were 1.5, 3.0, 10.0 and 40.0 mg/kg bw/day. Controls received powdered diet only.
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- Chlorothalonil
- EC Number:
- 217-588-1
- EC Name:
- Chlorothalonil
- Cas Number:
- 1897-45-6
- Molecular formula:
- C8Cl4N2
- IUPAC Name:
- tetrachlorobenzene-1,3-dicarbonitrile
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
Doses / concentrationsopen allclose all
- Dose / conc.:
- 15 mg/kg bw/day (nominal)
- Remarks:
- Group 2: Dietary equivalent to 1.54 and 1.50 mg/kg bw/day for males and females, respectively
- Dose / conc.:
- 30 mg/kg bw/day (nominal)
- Remarks:
- Group 3: Dietary equivalent to 3.04 and 3.10 mg/kg bw/day for males and females, respectively
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Remarks:
- Group 4: Dietary equivalent to 10.27 and 10.17 mg/kg bw/day for males and females, respectively
- Dose / conc.:
- 400 mg/kg bw/day (nominal)
- Remarks:
- Group 5: Dietary equivalent to 40.71 and 40.74 mg/kg bw/day for males and females, respectively
- Control animals:
- yes, plain diet
Results and discussion
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 10 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- histopathology: non-neoplastic
- organ weights and organ / body weight ratios
- Remarks on result:
- other:
- Remarks:
- Dietary equivalent to 10.3 and 10.2 mg/kg bw/day for males and females, respectively.
Target system / organ toxicity
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 30 mg/kg bw/day (nominal)
- System:
- urinary
- Organ:
- kidney
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- no
Any other information on results incl. tables
No
treatment-related clinical signs were recorded. Six rats died during the
study. None of these deaths was considered directly attributable to
treatment. No apparent treatment-related effect was seen. Marginally
lower alkaline phosphatase (AP) and glutamic-pyruvic transaminase (GPT)
levels were recorded in week 6 among males and females treated at 40
mg/kg bw/day. Lower AP levels were recorded among females treated at 40
mg/kg bw/day and all treated male groups in week 13. Lower GPT levels
were recorded among treated male and female groups at week 13. At weeks
19 and 26 during the withdrawal period these changes were not seen among
the treated male groups but lower AP values were recorded among the
treated female groups. Haematology, urinalysis, urine concentrating and
diluting tests and microbiological assay did not reveal any
treatment-related effects. No changes considered to be related to
treatment were seen at either the week 6 , week 13 or week 26 kills.
Higher kidney weights were recorded among males
treated at 40 or 10 mg/kg/day at the week 6 kill. Higher kidney weights
were recorded for males and females from all treated groups at the week
13 kill, although there was only a slight increase in weights among rats
treated at 1.5 mg/kg bw/day. Similar kidney weights were recorded for
males and females from all treated groups compared to the controls at
the termination of the withdrawal period. Slightly higher liver weights
were recorded at the 13-week kill for males treated at 40 mg/kg bw/day.
Liver weights recorded at the end of the withdrawal period for this
group were similar to control values. Treatment-related changes were
confined to the non-glandular epithelium of the stomach. There was an
increase in incidence of epithelial hyperplasia and hyperkeratosis among
rats treated with 10 or 40 mg/kg bw/day compared to the Controls. This
effect was seen at interim kill at 6 weeks after the start of dosing and
at termination at 13 weeks after the start of dosing. This increase in
incidence was not apparent in rats kept for the withdrawal period.
No NOAEL was derived in this study.
Applicant's summary and conclusion
- Conclusions:
- Based on effects on the liver and kidney the NOAEL is set on 10 ppm (dietary equivalent to 10.3 and 10.2 mg/kg bw/day for males and females, respectively).
- Executive summary:
Groups of Sprague-Dawley rats (25 per sex per dose) were exposed by admixture with the diet for 13 weeks of treatment followed by a 13-week withdrawal period for rats not killed at week 6 or 13 (no guideline, non-GLP). Exposure levels were 1.5, 3.0, 10.0 and 40.0 mg/kg bw/day. Controls received powdered diet only.
No treatment-related clinical signs were recorded. Six rats died during the study. None of these deaths was considered directly attributable to treatment. No apparent treatment-related effect was seen. Marginally lower alkaline phosphatase (AP) and glutamic-pyruvic transaminase (GPT) levels were recorded in week 6 among males and females treated at 40 mg/kg bw/day. Lower AP levels were recorded among females treated at 40 mg/kg bw/day and all treated male groups in week 13. Lower GPT levels were recorded among treated male and female groups at week 13. At weeks 19 and 26 during the withdrawal period these changes were not seen among the treated male groups but lower AP values were recorded among the treated female groups. Haematology, urinalysis, urine concentrating and diluting tests and microbiological assay did not reveal any treatment-related effects. No changes considered to be related to treatment were seen at either the week 6 , week 13 or week 26 kills. Higher kidney weights were recorded among males treated at 40 or 10 mg/kg/day at the week 6 kill. Higher kidney weights were recorded for males and females from all treated groups at the week 13 kill, although there was only a slight increase in weights among rats treated at 1.5 mg/kg bw/day. Similar kidney weights were recorded for males and females from all treated groups compared to the controls at the termination of the withdrawal period. Slightly higher liver weights were recorded at the 13-week kill for males treated at 40 mg/kg bw/day. Liver weights recorded at the end of the withdrawal period for this group were similar to control values. Treatment-related changes were confined to the non-glandular epithelium of the stomach. There was an increase in incidence of epithelial hyperplasia and hyperkeratosis among rats treated with 10 or 40 mg/kg bw/day compared to the Controls. This effect was seen at interim kill at 6 weeks after the start of dosing and at termination at 13 weeks after the start of dosing. This increase in incidence was not apparent in rats kept for the withdrawal period.
In conclusion, based on effects on the liver and kidney the NOAEL is set on 10 ppm (dietary equivalent to 10.3 and 10.2 mg/kg bw/day for males and females, respectively).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.